C12N 2770/16011
Caliciviridae
C12N2770/16011 (Caliciviridae) appears on 164 US grants and 241 published applications in this corpus.
Search patents in C12N- Granted patents
- 164
- Published applications
- 241
- Assignees
- 140
- Inventors
- 428
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 3 |
| 2003 | 4 | 6 |
| 2004 | 1 | 7 |
| 2005 | 4 | 7 |
| 2006 | 3 | 8 |
| 2007 | 4 | 4 |
| 2008 | 3 | 8 |
| 2009 | 7 | 8 |
| 2010 | 5 | 7 |
| 2011 | 7 | 10 |
| 2012 | 5 | 9 |
| 2013 | 5 | 13 |
| 2014 | 5 | 9 |
| 2015 | 3 | 5 |
| 2016 | 10 | 14 |
| 2017 | 6 | 7 |
| 2018 | 11 | 7 |
| 2019 | 10 | 8 |
| 2020 | 7 | 17 |
| 2021 | 5 | 10 |
| 2022 | 7 | 17 |
| 2023 | 13 | 15 |
| 2024 | 10 | 20 |
| 2025 | 10 | 14 |
| 2026 | 5 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/16034Use of virus or viral component as vaccineIndexing code102
- C12N 2770/16022New viral proteins or individual genes, new structural or functional aspects ofIndexing code62
- C12N 2770/16023Virus like particles [vlp]Indexing code54
- C12N 2770/16051Methods of production or purification of viral materialIndexing code22
- C12N 2770/16021Viruses as suchIndexing code16
- C12N 2770/16061Methods of inactivation or attenuationIndexing code11
- C12N 2770/16071Demonstrated in vivo effectIndexing code9
- C12N 2770/16041Use of virus, viral particle or viral elements as a vectorIndexing code6
All 12 subgroupsShow fewer
Recent patents
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Combined norovirus and rotavirus vaccine composition and methods of preparation31 Mar 2026US 12,589,144 B2Bharat Biotech International Limited
- Norovirus S particle based vaccines and methods of making and using same3 Feb 2026US 12,539,327 B2Children's Hospital Medical Center
- Artificial RNA molecules encoding a norovirus antigen and uses thereof20 Jan 2026US 12,527,856 B2CureVac AG
- Nucleic acid molecules and uses thereof6 Jan 2026US 12,514,918 B2CureVac AG
- Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor24 Sep 2026US 2026/0284173 A1Inthera Inc.
- Norovirus mrna vaccines10 Sep 2026US 2026/0263582 A1ModernaTX, Inc.
- System for regulating protein translation13 Aug 2026US 2026/0234645 A1National University Corporation Tokyo Medical and Dental University
- Methods of detection and removal of rhabdoviruses from cell lines30 Jul 2026US 2026/0217770 A1Takeda Vaccines, Inc.
- Trigger-inducible mrna circularization23 Jul 2026US 2026/0209789 A1Westlake University
Most cited
By later US patents
- Viral adjuvants48US 7,862,829 B2The University of North Carolina at Chapel Hill · 2011
- Antisense antiviral compound and method for treating ssRNA viral infection37US 8,906,872 B2Sarepta Therapeutics, Inc. · 2014
- Methods and reagents to detect and characterize Norwalk and related viruses35US 6,572,862 B1Baylor College of Medicine · 2003
- Norovirus and Sapovirus antigens35US 7,527,801 B2Novartis Vaccines and Diagnostics, Inc. · 2009
- Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses35US 9,474,759 B2Kansas State University Research Foundation · 2016